• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌——是时候采取行动了。

Hepatocellular carcinoma - time to take the ticket.

作者信息

Mullath Anju, Krishna Murali

机构信息

Department of Gastroenterology, Lakeshore Hospital and Research Centre, Kochi 682040, Kerala, India.

Department of Surgery, Military Hospital, Palampur 176061, Himachal Pradesh, India.

出版信息

World J Gastrointest Surg. 2019 Jun 27;11(6):287-295. doi: 10.4240/wjgs.v11.i6.287.

DOI:10.4240/wjgs.v11.i6.287
PMID:31367276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6658361/
Abstract

Hepatocellular carcinoma is one of the leading malignancies worldwide. Early detection of hepatocellular carcinoma and its management in the form of liver transplantation offers an attractive treatment option. The Milan criteria, proposed by Mazzaferro et al, have been the standard for selecting patients with hepatocellular carcinoma for transplantation. Recently, several studies have shown that even patients selected outside the Milan criteria can undergo transplantation with a relatively good outcome. This article examines the currently existing criteria other than the Milan criteria and also evaluates use of alpha-fetoprotein and positron emission tomography scans to predict the chance of recurrence.

摘要

肝细胞癌是全球主要的恶性肿瘤之一。早期检测肝细胞癌并通过肝移植进行治疗是一种有吸引力的治疗选择。Mazzaferro等人提出的米兰标准一直是选择肝细胞癌患者进行移植的标准。最近,多项研究表明,即使是不符合米兰标准的患者也可以接受移植,且预后相对较好。本文探讨了除米兰标准之外目前存在的其他标准,并评估了甲胎蛋白和正电子发射断层扫描在预测复发几率方面的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb32/6658361/affc4d903042/WJGS-11-287-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb32/6658361/6bd7052e1bfc/WJGS-11-287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb32/6658361/affc4d903042/WJGS-11-287-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb32/6658361/6bd7052e1bfc/WJGS-11-287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb32/6658361/affc4d903042/WJGS-11-287-g002.jpg

相似文献

1
Hepatocellular carcinoma - time to take the ticket.肝细胞癌——是时候采取行动了。
World J Gastrointest Surg. 2019 Jun 27;11(6):287-295. doi: 10.4240/wjgs.v11.i6.287.
2
Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria.超出米兰标准的肝细胞癌肝移植
Exp Clin Transplant. 2017 Mar;15(Suppl 2):59-64. doi: 10.6002/ect.TOND16.L16.
3
Impact of metabolic indices of F-fluorodeoxyglucose positron emission tomography/computed tomography on post transplantation recurrence of hepatocellular carcinoma.F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的代谢指标对肝癌移植后复发的影响。
J Cancer Res Clin Oncol. 2023 Apr;149(4):1401-1410. doi: 10.1007/s00432-022-04009-x. Epub 2022 Apr 22.
4
Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.活体肝移植:即使超出米兰标准,也是肝细胞癌的最佳治愈性治疗手段。
Cancer Control. 2021 Jan-Dec;28:10732748211011960. doi: 10.1177/10732748211011960.
5
Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.对于超出米兰标准的肝细胞癌,先进行降期治疗,然后进行肝移植。
Surgery. 2017 Dec;162(6):1250-1258. doi: 10.1016/j.surg.2017.08.007. Epub 2017 Oct 13.
6
Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach.中间型肝细胞癌的肝移植:一种适应性方法。
World J Gastroenterol. 2017 May 14;23(18):3195-3204. doi: 10.3748/wjg.v23.i18.3195.
7
Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.甲胎蛋白和 (18)F-FDG 正电子发射断层扫描比米兰标准更能预测活体供肝移植中的肿瘤复发。
J Hepatol. 2016 Apr;64(4):852-9. doi: 10.1016/j.jhep.2015.11.033. Epub 2015 Nov 30.
8
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
9
Hepatocellular carcinoma: when is liver transplantation oncologically futile?肝细胞癌:肝移植何时在肿瘤学上是徒劳的?
Transl Gastroenterol Hepatol. 2017 Jul 24;2:63. doi: 10.21037/tgh.2017.07.03. eCollection 2017.
10
Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.用于预测肝移植后肝细胞癌复发的生物标志物与米兰标准的组合
Liver Transpl. 2015 May;21(5):599-606. doi: 10.1002/lt.24117.

引用本文的文献

1
Long non-coding RNA CDKN2B-AS1 promotes hepatocellular carcinoma progression E2F transcription factor 1/G protein subunit alpha Z axis.长链非编码RNA CDKN2B-AS1通过E2F转录因子1/G蛋白亚基αZ轴促进肝细胞癌进展。
World J Gastrointest Oncol. 2023 Nov 15;15(11):1974-1987. doi: 10.4251/wjgo.v15.i11.1974.
2
[PreS1 Antigen of HBV Down-Regulates MHC-Ⅰ on the Surface of Hepatocytes and Promotes Hepatocarcinogenesis].[乙肝病毒前S1抗原下调肝细胞表面的主要组织相容性复合体Ⅰ类分子并促进肝癌发生]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Mar;53(2):285-290. doi: 10.12182/20220360509.
3
A novel circular RNA circ-LRIG3 facilitates the malignant progression of hepatocellular carcinoma by modulating the EZH2/STAT3 signaling.

本文引用的文献

1
Transarterial Chemoembolization (TACE) Combined with Sorafenib TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study.经动脉化疗栓塞术(TACE)联合索拉非尼与单纯TACE治疗不可切除肝细胞癌的倾向评分匹配研究
J Cancer. 2019 Jan 29;10(5):1189-1196. doi: 10.7150/jca.28994. eCollection 2019.
2
Time to recurrence, but not recurrence-free survival, should be the endpoint used to predict early recurrence after HCC resection.复发时间而非无复发生存期,应作为预测肝癌切除术后早期复发的终点指标。
J Hepatol. 2019 Mar;70(3):570-571. doi: 10.1016/j.jhep.2018.10.025. Epub 2018 Dec 13.
3
Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection.
一种新型环状RNA circ-LRIG3通过调节EZH2/STAT3信号通路促进肝细胞癌的恶性进展。
J Exp Clin Cancer Res. 2020 Nov 23;39(1):252. doi: 10.1186/s13046-020-01779-5.
4
OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma.OSlihc:一种用于肝细胞癌的在线预后生物标志物分析工具。
Front Pharmacol. 2020 Jun 10;11:875. doi: 10.3389/fphar.2020.00875. eCollection 2020.
5
Mitofusin-2 (Mfn-2) Might Have Anti-Cancer Effect through Interaction with Transcriptional Factor SP1 and Consequent Regulation on Phosphatidylinositol Transfer Protein 3 (PITPNM3) Expression.线粒体融合蛋白 2(Mfn-2)可能通过与转录因子 SP1 相互作用并随后调节磷酸肌醇转移蛋白 3(PITPNM3)的表达来发挥抗癌作用。
Med Sci Monit. 2020 Jan 19;26:e918599. doi: 10.12659/MSM.918599.
18F-氟脱氧葡萄糖正电子发射断层扫描在接受手术切除的肝细胞癌患者中的临床应用价值
Ann Hepatobiliary Pancreat Surg. 2017 Nov;21(4):194-198. doi: 10.14701/ahbps.2017.21.4.194. Epub 2017 Nov 30.
4
Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant?正电子发射断层扫描/计算机断层扫描在接受肝移植的肝细胞癌患者中的应用。有用、必要还是无关?
Eur J Radiol. 2017 Jun;91:155-159. doi: 10.1016/j.ejrad.2017.03.013. Epub 2017 Mar 23.
5
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
6
Up-to-7 Criteria for Hepatocellular Carcinoma Liver Transplantation: A Retrospective Analysis of Experiences.肝细胞癌肝移植的7项及以下标准:经验回顾性分析
Transplant Proc. 2016 Nov;48(9):2969-2972. doi: 10.1016/j.transproceed.2016.08.035.
7
Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.利用总肿瘤大小和(18)F-氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描对肝细胞癌患者活体肝移植提出新的扩展选择标准:韩国国立癌症中心标准
World J Transplant. 2016 Jun 24;6(2):411-22. doi: 10.5500/wjt.v6.i2.411.
8
The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.扩大的多伦多标准用于肝癌患者的肝移植:一项前瞻性验证研究。
Hepatology. 2016 Dec;64(6):2077-2088. doi: 10.1002/hep.28643. Epub 2016 Jun 30.
9
Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry.经动脉化疗栓塞术(TACE)与索拉非尼在不可切除肝细胞癌患者中的应用:GIDEON注册研究的美国区域分析
Liver Cancer. 2016 Feb;5(1):37-46. doi: 10.1159/000367757. Epub 2015 Dec 15.
10
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC:SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.